Bullish on Biocon: Prakash Diwan, Altamount Capital

In a chat with ET Now, Prakash Diwan, Director, Altamount Capital, shares his views on pharma.

ET Now: What about large cap pharma, what are your bets there?

Prakash Diwan: I love Biocon at these valuations. After the numbers we have seen, they recede into not so fancied kind of zone but if you see the build up that Biocon would be getting into and the kind of shortage there still exists for its products, it is absolutely imperative that it will start firing in.

They had a slowdown somewhere this time around but otherwise once they catch up with that lost phase, Biocon should probably be the stock that could move into that 550-570 kind of zone.